Advanced search

Vol 31, No 2 (2024)
Review Article
Published online: 2024-01-22

open access

View PDF Download PDF file
Page views 1272
Article views/downloads 672
Get Citation

Connect on Social Media

Connect on Social Media

Advances in myocarditis management in the light of the latest research and recent guidelines of the European Society of Cardiology

Aleksandra Chabior1, Agata Tymińska1, Agnieszka Pawlak2, Andrea Giordani3, Alida Caforio3, Marcin Grabowski1, Krzysztof Ozierański1
DOI: 10.5603/cj.95175
Pubmed: 38247433
Cardiol J 2024;31(2):342-351.

Abstract

Myocarditis remains an unknown disease with varying clinical manifestations, often leading to heart failure. The latest 2021 and 2022 guidelines of the European Society of Cardiology (ESC) are the first official European documents updating knowledge on the diagnosis and treatment of myocarditis since the 2013 ESC expert consensus statement. These guidelines and new studies allow standardization and improvements to the management of myocarditis. In this review, we discuss the most important aspects of myocarditis diagnosis, therapies and follow-up based on current knowledge.

Keywords: cardio-immunologyheart failureinflammatory cardiomyopathyimmunosuppressionendomyocardial biopsypersonalized medicine

Article available in PDF format

View PDF Download PDF file

References

  1. Lynge TH, Nielsen TS, Gregers Winkel Bo, et al. Sudden cardiac death caused by myocarditis in persons aged 1-49 years: a nationwide study of 14 294 deaths in Denmark. Forensic Sci Res. 2019; 4(3): 247–256.
    CrossRefPubMed
  2. Ozierański K, Tymińska A, Chabior A, et al. Sex differences in incidence, management, and outcomes in adult patients aged over 20 years with clinically diagnosed myocarditis in the last 10 years: data from the MYO‑PL nationwide database. Pol Arch Intern Med. 2022; 132(4).
    CrossRefPubMed
  3. Ammirati E, Cipriani M, Moro C, et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis. Circulation. 2018; 138(11): 1088–1099.
    CrossRef
  4. Ozierański K, Tymińska A, Kruk M, et al. Occurrence, trends, management and outcomes of patients hospitalized with clinically suspected myocarditis-ten-year perspectives from the MYO-PL nationwide database. J Clin Med. 2021; 10(20).
    CrossRefPubMed
  5. Ozieranski K, Tyminska A, Jonik S, et al. Clinically suspected myocarditis in the course of severe acute respiratory syndrome novel coronavirus-2 infection: fact or fiction? J Card Fail. 2021; 27(1): 92–96.
    CrossRefPubMed
  6. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC]. G Ital Cardiol (Rome). 2022; 23(4): e1–e127.
  7. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013; 34(33): 2636–2648.
    CrossRefPubMed
  8. Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022; 23(10): e333–e465.
    CrossRefPubMed
  9. Zeppenfeld K, Tfelt-Hansen J, de Riva M. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40): 3997–4126.
    CrossRef
  10. Martens CR, Accornero F. Viruses in the heart: direct and indirect routes to myocarditis and heart failure. Viruses. 2021; 13(10): 1924.
    CrossRefPubMed
  11. Fijolek J, Gawryluk D, Piotrowska-Kownacka D, et al. Chest pain of atypical cause in a young man. Diagnostics (Basel). 2022; 12(8): 1881.
    CrossRefPubMed
  12. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021; 9(6): e002435.
    CrossRefPubMed
  13. Campuzano O, Fernández-Falgueras A, Sarquella-Brugada G, et al. A genetically vulnerable myocardium may predispose to myocarditis. J Am Coll Cardiol. 2015; 66(25): 2913–2914.
    CrossRefPubMed
  14. Artico J, Merlo M, Delcaro G, et al. Lymphocytic myocarditis: a genetically predisposed disease? J Am Coll Cardiol. 2020; 75(24): 3098–3100.
    CrossRefPubMed
  15. Tschöpe C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021; 18(3): 169–193.
    CrossRefPubMed
  16. Lauer B, Niederau C, Kühl U, et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol. 1997; 30(5): 1354–1359.
    CrossRefPubMed
  17. Williams MGL, Liang K, De Garate E, et al. Peak troponin and CMR to guide management in suspected ACS and nonobstructive coronary arteries. JACC Cardiovasc Imaging. 2022; 15(9): 1578–1587.
    CrossRefPubMed
  18. Tymińska A, Ozierański K, Balsam P, et al. The prevalence and association of major ECG abnormalities with clinical characteristics and the outcomes of real-life heart failure patients: Heart Failure Registries of the Eu ropean Society of Cardiology. Kardiol Pol. 2021; 79(9): 980–987.
    CrossRefPubMed
  19. Buttà C, Zappia L, Laterra G, et al. Diagnostic and prognostic role of electrocardiogram in acute myocarditis: A comprehensive review. Ann Noninvasive Electrocardiol. 2020; 25(3): e12726.
    CrossRefPubMed
  20. Kasner M, Sinning D, Escher F, et al. The utility of speckle tracking imaging in the diagnostic of acute myocarditis, as proven by endomyocardial biopsy. Int J Cardiol. 2013; 168(3): 3023–3024.
    CrossRefPubMed
  21. Sperlongano S, D'Amato A, Tagliamonte E, et al. Acute myocarditis: prognostic role of speckle tracking echocardiography and comparison with cardiac magnetic resonance features. Heart Vessels. 2022; 37(1): 121–131.
    CrossRefPubMed
  22. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018; 72(24): 3158–3176.
    CrossRefPubMed
  23. Gannon MP, Schaub E, Grines CL, et al. State of the art: Evaluation and prognostication of myocarditis using cardiac MRI. J Magn Reson Imaging. 2019; 49(7): e122–e131.
    CrossRefPubMed
  24. Biesbroek PS, Hirsch A, Zweerink A, et al. Additional diagnostic value of CMR to the European Society of Cardiology (ESC) position statement criteria in a large clinical population of patients with suspected myocarditis. Eur Heart J Cardiovasc Imaging. 2018; 19(12): 1397–1407.
    CrossRefPubMed
  25. Kadkhodayan A, Chareonthaitawee P, Raman SV, et al. Imaging of Inflammation in Unexplained Cardiomyopathy. JACC Cardiovasc Imaging. 2016; 9(5): 603–617.
    CrossRefPubMed
  26. Robinson AA, Chow K, Salerno M. Myocardial T1 and ECV measurement: underlying concepts and technical considerations. JACC Cardiovasc Imaging. 2019; 12(11 Pt 2): 2332–2344.
    CrossRefPubMed
  27. Kuruvilla S, Adenaw N, Katwal AB, et al. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014; 7(2): 250–258.
    CrossRefPubMed
  28. Grün S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012; 59(18): 1604–1615.
    CrossRefPubMed
  29. Alba AC, Gaztañaga J, Foroutan F, et al. Prognostic value of late gadolinium enhancement for the prediction of cardiovascular outcomes in dilated cardiomyopathy: an international, multi-institutional study of the MINICOR group. Circ Cardiovasc Imaging. 2020; 13(4): e010105.
    CrossRefPubMed
  30. Jeserich M, Konstantinides S, Pavlik G, et al. Non-invasive imaging in the diagnosis of acute viral myocarditis. Clin Res Cardiol. 2009; 98(12): 753–763.
    CrossRefPubMed
  31. Aquaro GD, Perfetti M, Camastra G, et al. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY study. J Am Coll Cardiol. 2017; 70(16): 1977–1987.
    CrossRefPubMed
  32. Gräni C, Eichhorn C, Bière L, et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol. 2017; 70(16): 1964–1976.
    CrossRefPubMed
  33. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006; 114(15): 1581–1590.
    CrossRefPubMed
  34. Ammirati E, Frigerio M, Adler ED, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail. 2020; 13(11): e007405.
    CrossRefPubMed
  35. Iles L, Pfluger H, Lefkovits L, et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011; 57(7): 821–828.
    CrossRefPubMed
  36. Lagan J, Fortune C, Hutchings D, et al. The diagnostic and prognostic utility of contemporary cardiac magnetic resonance in suspected acute myocarditis. Diagnostics (Basel). 2022; 12(1).
    CrossRefPubMed
  37. Anzini M, Merlo M, Sabbadini G, et al. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. Circulation. 2013; 128(22): 2384–2394.
    CrossRefPubMed
  38. Tymińska A, Ozierański K, Caforio ALP, et al. Emerging nuclear medicine modalities to improve diagnostic accuracy in myocarditis. Kardiol Pol. 2020; 78(12): 1297–1298.
    CrossRefPubMed
  39. Caforio AL, Cheng C, Perazzolo Marra M, et al. How to improve therapy in myocarditis: role of cardiovascular magnetic resonance and of endomyocardial biopsy. Eur Heart J Suppl. 2019; 21(Suppl B): B19–B22.
    CrossRefPubMed
  40. Chimenti C, Frustaci A. Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period. Circulation. 2013; 128(14): 1531–1541.
    CrossRefPubMed
  41. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008; 29(17): 2073–2082.
    CrossRefPubMed
  42. McCarthy RE, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000; 342(10): 690–695.
    CrossRefPubMed
  43. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79(17): e263–e421.
    CrossRefPubMed
  44. Sinagra G, Anzini M, Pereira NL, et al. Myocarditis in clinical practice. Mayo Clin Proc. 2016; 91(9): 1256–1266.
    CrossRefPubMed
  45. Montero S, Abrams D, Ammirati E, et al. Fulminant myocarditis in adults: a narrative review. J Geriatr Cardiol. 2022; 19(2): 137–151.
    CrossRefPubMed
  46. Chen YS, Wang MJ, Chou NK, et al. Rescue for acute myocarditis with shock by extracorporeal membrane oxygenation. Ann Thorac Surg. 1999; 68(6): 2220–2224.
    CrossRefPubMed
  47. Tavecchia A, Giovanni A, Cartella A, et al. Future perspectives in acute myocarditis complicated by cardiogenic shock. J Shock Hemodynamics. 2022; 1(2): E2022123.
  48. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021; 42(35): 3427–3520.
    CrossRefPubMed
  49. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021; 9(6).
    CrossRefPubMed
  50. Zhang L, Zlotoff DA, Awadalla M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020; 141(24): 2031–2034.
    CrossRefPubMed
  51. Lyon AR, López-Fernández T, Couch LS. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.
    CrossRefPubMed
  52. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009; 30(16): 1995–2002.
    CrossRefPubMed
  53. Kociol RD, Cooper LT, Fang JC, et al. Recognition and initial management of fulminant myocarditis: a Scientific Statement from the American Heart Association. Circulation. 2020; 141(6): e69–e92.
    CrossRefPubMed
  54. Cooper LT, Hare JM, Tazelaar HD, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol. 2008; 102(11): 1535–1539.
    CrossRefPubMed
  55. Mankad R, Bonnichsen C, Mankad S. Hypereosinophilic syndrome: cardiac diagnosis and management. Heart. 2016; 102(2): 100–106.
    CrossRefPubMed
  56. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001; 104(1): 39–45.
    CrossRefPubMed
  57. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009; 30(16): 1995–2002.
    CrossRefPubMed
  58. Chimenti C, Russo MA, Frustaci A. Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. Eur Heart J. 2022; 43(36): 3463–3473.
    CrossRefPubMed
  59. Ozierański K, Tymińska A, Marchel M, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus-negative myocarditis or inflammatory cardiomyopathy (IMPROVE-MC). Cardiol J. 2022; 29(2): 329–341.
    CrossRefPubMed
  60. Ozieranski K, Tyminska A, Caforio ALP. Immunosuppressive therapy of myocarditis and inflammatory cardiomyopathy in the light of new data. Eur Heart J. 2022; 43(45): 4758–4759.
    CrossRefPubMed
  61. Schultheiss HP, Piper C, Sowade O, et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-beta treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol. 2016; 105(9): 763–773.
    CrossRefPubMed
  62. Kühl U, Lassner D, von Schlippenbach J, et al. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol. 2012; 60(14): 1295–1296.
    CrossRefPubMed
  63. Mahfoud F, Gärtner B, Kindermann M, et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J. 2011; 32(7): 897–903.
    CrossRefPubMed
  64. Dennert R, Velthuis S, Schalla S, et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther. 2010; 15(2): 193–201.
    CrossRefPubMed
  65. Huang X, Sun Y, Su G, et al. Intravenous immunoglobulin therapy for acute myocarditis in children and adults. Int Heart J. 2019; 60(2): 359–365.
    CrossRefPubMed
  66. Yen CY, Hung MC, Wong YC, et al. Role of intravenous immunoglobulin therapy in the survival rate of pediatric patients with acute myocarditis: A systematic review and meta-analysis. Sci Rep. 2019; 9(1): 10459.
    CrossRefPubMed
  67. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021; 42(1): 17–96.
    CrossRefPubMed
  68. Tymińska A, Ozierański K, Skwarek A, et al. Personalized management of myocarditis and inflammatory cardiomyopathy in clinical practice. J Pers Med. 2022; 12(2): 183.
    CrossRefPubMed
  69. Caforio ALP, Baritussio A, Marcolongo R, et al. Serum anti-heart and anti-intercalated disk autoantibodies: novel autoimmune markers in cardiac sarcoidosis. J Clin Med. 2021; 10(11).
    CrossRefPubMed
  70. Caforio ALP. Myocarditis: endomyocardial biopsy and circulating anti-heart autoantibodies are key to diagnosis and personalized etiology-directed treatment. Eur Heart J. 2021; 42(16): 1618–1620.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice